| Cover - shares | 9 Months Ended | |
| Sep. 30, 2023 | Oct. 31, 2023 | |
| Cover [Abstract] | ||
| Document Type | 10-Q | |
| Amendment Flag | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Sep. 30, 2023 | |
| Document Fiscal Period Focus | Q3 | |
| Document Fiscal Year Focus | 2023 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity File Number | 000-51074 | |
| Entity Registrant Name | BIOFORCE NANOSCIENCES HOLDINGS, INC. | |
| Entity Central Index Key | 0001310488 | |
| Entity Tax Identification Number | 74-3078125 | |
| Entity Incorporation, State or Country Code | NV | |
| Entity Address, Address Line One | 2020 General Booth Blvd. | |
| Entity Address, Address Line Two | Unit 230 | |
| Entity Address, City or Town | Virginia Beach | |
| Entity Address, State or Province | VA | |
| Entity Address, Postal Zip Code | 23454 | |
| City Area Code | (757) | |
| Local Phone Number | 306-6090 | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 29,271,755 |
| CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
| Current Assets | ||
| Cash | $ 686 | $ 734 |
| Total Current Assets | 686 | 734 |
| Total Assets | 686 | 734 |
| Current Liabilities | ||
| Accounts Payable and Accrued Expenses | 1,075 | 398 |
| Accrued Board of Directors Compensation | 1,490,767 | 1,173,517 |
| Due to Related Parties | 213,664 | 174,096 |
| Total Current Liabilities | 1,705,506 | 1,348,011 |
| Total Liabilities | 1,705,506 | 1,348,011 |
| Stockholders’ Deficit | ||
| Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 29,271,755 Issued and Outstanding, Respectively | 29,272 | 29,272 |
| Additional Paid-In-Capital | 158,781,227 | 158,781,227 |
| Accumulated Deficit | (160,515,319) | (160,157,776) |
| Total Stockholders’ Deficit | (1,704,820) | (1,347,277) |
| Total Liabilities and Stockholders’ Deficit | $ 686 | $ 734 |
| CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED (Parenthetical) - $ / shares | Sep. 30, 2023 | Dec. 31, 2022 |
| Statement of Financial Position [Abstract] | ||
| Common stock, par value | $ 0.001 | $ 0.001 |
| Common stock, shares authorized | 900,000,000 | 900,000,000 |
| Common stock, shares issued | 29,271,755 | 29,271,755 |
| Common stock, shares outstanding | 29,271,755 | 29,271,755 |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED - USD ($) | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Sales | ||||
| Cost of Sales | ||||
| Gross Profit | ||||
| Operating Expenses | ||||
| Board of Directors Compensation | 105,750 | 105,750 | 317,250 | 317,250 |
| General and Administrative | 7,857 | 16,837 | 40,293 | 53,529 |
| Total Expenses | 113,607 | 122,587 | 357,543 | 370,779 |
| Net Loss for the Period | $ (113,607) | $ (122,587) | $ (357,543) | $ (370,779) |
| Weighted Average Number of Common Shares - Basic | 29,271,755 | 29,271,755 | 29,271,755 | 29,271,755 |
| Weighted Average Number of Common Shares - Diluted | 29,271,755 | 29,271,755 | 29,271,755 | 29,271,755 |
| Net Loss for the Period Per Common Shares - Basic | $ 0 | $ 0 | $ 0.01 | $ 0.01 |
| Net Loss for the Period Per Common Shares - Diluted | $ 0 | $ 0 | $ 0.01 | $ 0.01 |
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED - USD ($) | 9 Months Ended | |
| Sep. 30, 2023 | Sep. 30, 2022 | |
| Cash Flows from Operating Activities | ||
| Net Loss for the Period | $ (357,543) | $ (370,779) |
| Changes in Assets and Liabilities: | ||
| Prepaid Expenses | 40 | |
| Accounts Payable and Accrued Expenses | 677 | (5,469) |
| Accrued Board of Directors Compensation | 317,250 | 317,250 |
| Net Cash Flows Used In Operating Activities | (39,616) | (58,958) |
| Cash Flows from Investing Activities | ||
| Cash Flows from Financing Activities | ||
| Capital Contributions | 100 | |
| Proceeds from Related Parties | 39,568 | 48,503 |
| Net Cash Flows Provided by Financing Activities | 39,568 | 48,603 |
| Net Change in Cash | (48) | (10,355) |
| Cash - Beginning of Period | 734 | 11,105 |
| Cash - End of Period | 686 | 750 |
| Cash Paid During the Period for: | ||
| Interest | ||
| Income Taxes | ||
| CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT UNAUDITED - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
| Balance - June 30, 2023 at Dec. 31, 2021 | $ 29,272 | $ 158,781,127 | $ (159,672,262) | $ (861,863) |
| Beginning balance, shares at Dec. 31, 2021 | 29,271,755 | |||
| Net Loss for the Period | (132,408) | (132,408) | ||
| Balance - September 30, 2023 at Mar. 31, 2022 | $ 29,272 | 158,781,127 | (159,804,670) | (994,271) |
| Ending balance, shares at Mar. 31, 2022 | 29,271,755 | |||
| Net Loss for the Period | (115,784) | (115,784) | ||
| Balance - September 30, 2023 at Jun. 30, 2022 | $ 29,272 | 158,781,127 | (159,920,454) | (1,110,055) |
| Ending balance, shares at Jun. 30, 2022 | 29,271,755 | |||
| Capital Contribution | 100 | 100 | ||
| Net Loss for the Period | (122,587) | (122,587) | ||
| Balance - September 30, 2023 at Sep. 30, 2022 | $ 29,272 | 158,781,227 | (160,043,041) | (1,232,542) |
| Ending balance, shares at Sep. 30, 2022 | 29,271,755 | |||
| Balance - June 30, 2023 at Dec. 31, 2022 | $ 29,272 | 158,781,227 | (160,157,776) | (1,347,277) |
| Beginning balance, shares at Dec. 31, 2022 | 29,271,755 | |||
| Net Loss for the Period | (130,005) | (130,005) | ||
| Balance - September 30, 2023 at Mar. 31, 2023 | $ 29,272 | 158,781,227 | (160,287,781) | (1,477,282) |
| Ending balance, shares at Mar. 31, 2023 | 29,271,755 | |||
| Net Loss for the Period | (113,931) | (113,931) | ||
| Balance - September 30, 2023 at Jun. 30, 2023 | $ 29,272 | 158,781,227 | (160,401,712) | (1,591,213) |
| Ending balance, shares at Jun. 30, 2023 | 29,271,755 | |||
| Net Loss for the Period | (113,607) | (113,607) | ||
| Balance - September 30, 2023 at Sep. 30, 2023 | $ 29,272 | $ 158,781,227 | $ (160,515,319) | $ (1,704,820) |
| Ending balance, shares at Sep. 30, 2023 | 29,271,755 |
| Organization & Description of Business | 9 Months Ended |
| Sep. 30, 2023 | |
| Accounting Policies [Abstract] | |
| Organization & Description of Business | NOTE 1 – Organization & Description of Business The Company was incorporated in the State of Nevada on December 10, 1999 as Silver River Ventures, Inc. On February 24, 2006, the Company completed the acquisition of BioForce Nanosciences Holdings Inc. (“BioForce”), a Delaware corporation, and changed the corporate name at that time. On May 6, 2020, the Company purchased 100,000 1,000 |
| Summary of Significant Accounting Policies | 9 Months Ended |
| Sep. 30, 2023 | |
| Accounting Policies [Abstract] | |
| Summary of Significant Accounting Policies | NOTE 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated balance sheet has been derived from the December 31, 2022 audited financial statements and the unaudited condensed consolidated financial statements as of September 30, 2023 and 2022, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and nine months ended September 30, 2023, are not necessarily indicative of the results of operations expected for the year ending December 31, 2023. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Element Global, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Earnings (Loss) per Share Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share. Stock-Based Compensation We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation—Stock Compensation, Fair Value of Financial Instruments The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates. Revenue Recognition The Company implemented ASC 606, Revenue from Contracts with Customers The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation. |
| Recently Issued Accounting Standards | 9 Months Ended |
| Sep. 30, 2023 | |
| Accounting Changes and Error Corrections [Abstract] | |
| Recently Issued Accounting Standards | NOTE 3 – Recently Issued Accounting Standards The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements, including the new lease standard. The Company does not have any leases and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. |
| Going Concern | 9 Months Ended |
| Sep. 30, 2023 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| Going Concern | NOTE 4 – Going Concern The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has reported recurring losses from operations and has net current liabilities and an accumulated deficit. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. While the Company is attempting to continue operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management believes that the actions presently being taken to further implement the Company’s business plan; to expand sales with a dynamic marketing campaign and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. During the nine months ended September 30, 2023, due to lack of revenues the officers of the Company paid for all expenses through loans to the Company. This allowed the Company to continue as a going concern. |
| Related Party Transactions | 9 Months Ended |
| Sep. 30, 2023 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | NOTE 5 – Related Party Transactions The Company’s Director, Secretary and Acting CFO, Richard Kaiser, is the operator of Yes International, a full-service investor relations firm. He handles duties of the Company regarding his officer capacities as the Secretary and Acting CFO, but also provides investor relations services through Yes International for the Company at no charge. During the nine months ended September 30, 2023 and 2022, two board of directors paid expenses of the Company in the amount of $ 39,568 48,503 213,664 174,096 |
| Stock | 9 Months Ended |
| Sep. 30, 2023 | |
| Equity [Abstract] | |
| Stock | NOTE 6 – Stock Preferred Stock Preferred stock consists of 100,000,000 0.001 10,000,000 Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock. 0 Common Stock Common stock consists of 900,000,000 0.001 5 to 1 reverse split 29,271,755 |
| Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
| Sep. 30, 2023 | |
| Accounting Policies [Abstract] | |
| Basis of Presentation | Basis of Presentation The accompanying condensed consolidated balance sheet has been derived from the December 31, 2022 audited financial statements and the unaudited condensed consolidated financial statements as of September 30, 2023 and 2022, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and nine months ended September 30, 2023, are not necessarily indicative of the results of operations expected for the year ending December 31, 2023. |
| Principles of Consolidation | Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Element Global, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation. |
| Use of Estimates | Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
| Earnings (Loss) per Share | Earnings (Loss) per Share Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share. |
| Stock-Based Compensation | Stock-Based Compensation We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation—Stock Compensation, |
| Fair Value of Financial Instruments | Fair Value of Financial Instruments The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates. |
| Revenue Recognition | Revenue Recognition The Company implemented ASC 606, Revenue from Contracts with Customers The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation. |
| Organization & Description of Business (Details Narrative) | May 06, 2020 USD ($) shares |
| Accounting Policies [Abstract] | |
| Number of shares purchased | shares | 100,000 |
| Payment to acquire subsidiary | $ | $ 1,000 |
| Related Party Transactions (Details Narrative) - USD ($) | 9 Months Ended | ||
| Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
| Related Party Transactions [Abstract] | |||
| Expenses | $ 39,568 | $ 48,503 | |
| Due to related parties | $ 213,664 | $ 174,096 | |
| Stock (Details Narrative) - $ / shares | 1 Months Ended | 9 Months Ended | |
| Nov. 25, 2019 | Sep. 30, 2023 | Dec. 31, 2022 | |
| Class of Stock [Line Items] | |||
| Preferred stock, shares authorized | 100,000,000 | 100,000,000 | |
| Preferred stock, par value | $ 0.001 | $ 0.001 | |
| Preferred stock conversion basis | Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock. | ||
| Common stock, shares authorized | 900,000,000 | 900,000,000 | |
| Common stock, par value | $ 0.001 | $ 0.001 | |
| Reverse stock split | 5 to 1 reverse split | ||
| Common stock, shares, issued | 29,271,755 | 29,271,755 | |
| Common stock, shares, outstanding | 29,271,755 | 29,271,755 | |
| Series A Preferred Stock [Member] | |||
| Class of Stock [Line Items] | |||
| Preferred stock, shares authorized | 10,000,000 | 10,000,000 | |
| Preferred stock, shares issued | 0 | 0 | |
| Preferred stock, shares outstanding | 0 | 0 |
